» Articles » PMID: 31186781

Clinical Associations and Prognostic Value of Site-specific Metastases in Non-small Cell Lung Cancer: A Population-based Study

Overview
Journal Oncol Lett
Specialty Oncology
Date 2019 Jun 13
PMID 31186781
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The prognosis of non-small cell lung cancer (NSCLC) is poor, particularly for patients with metastatic disease. Numerous efforts have been made to improve the prognosis of these patients; however, only a small number of studies have explored the occurrence rate and prognostic value of different patterns of distant metastasis (DM) in NSCLC systematically. To investigate these, information from patients diagnosed with NSCLC between 2010 and 2014 was collected from the Surveillance, Epidemiology and End Results database. Survival rate comparisons were performed using Kaplan-Meier analysis and log-rank tests. A Cox proportional hazard model was established to determine factors associated with improved overall survival (OS) and cancer-specific survival (CSS). The present study revealed that the most common site of single metastasis occurrence was bone, and the least common was the liver for NSCLC. As for multi-site metastases, the most common two-site metastasis involved bone and lung, and the most common three-site metastasis involved bone, liver and lung. As for NSCLC subtypes, large cell carcinoma (LCC) exhibited more specific metastatic features. The most common single metastatic site was the brain for patients with LCC, and the most common two-site metastatic combination was bone and liver. Patients with isolated liver metastasis exhibited the worst OS and CSS among patients with single metastasis. Furthermore, for patients with multi-site metastases, metastases involving the liver were associated with the worst OS and CSS among various combinations. To the best of our knowledge, the present study is the first to investigate the occurrence rate and prognostic value of different metastatic patterns of site-specific DM for NSCLC using a large population-based dataset. The findings of the present study may have vital implications for classifying patients with advanced NSCLC, thus laying a foundation for individualized precise treatment.

Citing Articles

Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8CD69 T cells.

Tang S, Tang R, Chen G, Zhang D, Lin K, Yang H J Immunother Cancer. 2024; 12(12).

PMID: 39694701 PMC: 11660327. DOI: 10.1136/jitc-2024-009543.


Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.

Sharma R, Sharma S, Shriwas P, Mehta L, Vu A, Mouw J iScience. 2024; 27(11):111133.

PMID: 39524367 PMC: 11544388. DOI: 10.1016/j.isci.2024.111133.


Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database.

Xie T, Qiu B, Luo J, Diao Y, Hu L, Liu X Sci Rep. 2024; 14(1):22445.

PMID: 39341901 PMC: 11438988. DOI: 10.1038/s41598-024-73389-6.


Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.

Zhang T, Zhang Y, Ni Y, Jia X, Li Y, Mao Z Thorac Cancer. 2024; 15(26):1897-1911.

PMID: 39098998 PMC: 11462952. DOI: 10.1111/1759-7714.15417.


Real-world analysis of first-line afatinib in patients with -mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors.

Kim J, Jang T, Choi C, Kim M, Yong Lee S, Park C Transl Lung Cancer Res. 2023; 12(6):1197-1209.

PMID: 37425421 PMC: 10326794. DOI: 10.21037/tlcr-22-832.


References
1.
Postmus P, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz Jr E . The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007; 2(8):686-93. DOI: 10.1097/JTO.0b013e31811f4703. View

2.
Morgensztern D, Ng S, Gao F, Govindan R . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2009; 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c. View

3.
Crino L, Weder W, Van Meerbeeck J, Felip E . Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v103-15. DOI: 10.1093/annonc/mdq207. View

4.
Griffioen G, Toguri D, Dahele M, Warner A, De Haan P, Rodrigues G . Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer. 2013; 82(1):95-102. DOI: 10.1016/j.lungcan.2013.07.023. View

5.
He Y, Zhang X, Yang J, Niu F, Zeng Z, Yan H . Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. Clin Lung Cancer. 2014; 15(6):441-7. DOI: 10.1016/j.cllc.2014.06.006. View